AJP - Endo Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 291: E1144-E1150, 2006. First published February 14, 2006; doi:10.1152/ajpendo.00571.2005
0193-1849/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/E1144    most recent
00571.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muscelli, E.
Right arrow Articles by Ferrannini, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muscelli, E.
Right arrow Articles by Ferrannini, E.

Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance

Elza Muscelli,1 Andrea Mari,2 Andrea Natali,1 Brenno D. Astiarraga,1 Stefania Camastra,1 Silvia Frascerra,1 Jens J. Holst,3 and Ele Ferrannini1

1Department of Internal Medicine and Consiglio Nazionale delle Ricerche (CNR) Institute of Clinical Physiology, University of Pisa; 2CNR Institute of Biochemical Engineering, Padua, Italy; and 3Department of Medical Physiology, Panum Institute, Copenhagen, Denmark

Submitted 21 November 2005 ; accepted in final form 9 February 2006

The mechanisms by which the enteroinsular axis influences beta-cell function have not been investigated in detail. We performed oral and isoglycemic intravenous (IV) glucose administration in subjects with normal (NGT; n = 11) or impaired glucose tolerance (IGT; n = 10), using C-peptide deconvolution to calculate insulin secretion rates and mathematical modeling to quantitate beta-cell function. The incretin effect was taken to be the ratio of oral to IV responses. In NGT, incretin-mediated insulin release [oral glucose tolerance test (OGTT)/IV ratio = 1.59 ± 0.18, P = 0.004] amounted to 18 ± 2 nmol/m2 (32 ± 4% of oral response), and its time course matched that of total insulin secretion. The beta-cell glucose sensitivity (OGTT/IV ratio = 1.52 ± 0.26, P = 0.02), rate sensitivity (response to glucose rate of change, OGTT/IV ratio = 2.22 ± 0.37, P = 0.06), and glucose-independent potentiation were markedly higher with oral than IV glucose. In IGT, beta-cell glucose sensitivity (75 ± 14 vs. 156 ± 28 pmol·min–1·m–2·mM–1 of NGT, P = 0.01) and potentiation were impaired on the OGTT. The incretin effect was not significantly different from NGT in terms of plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide responses, total insulin secretion, and enhancement of beta-cell glucose sensitivity (OGTT/IV ratio = 1.73 ± 0.24, P = NS vs. NGT). However, the time courses of incretin-mediated insulin secretion and potentiation were altered, with a predominance of glucose-induced vs. incretin-mediated stimulation. We conclude that, under physiological circumstances, incretin-mediated stimulation of insulin secretion results from an enhancement of all dynamic aspects of beta-cell function, particularly beta-cell glucose sensitivity. In IGT, beta-cell function is inherently impaired, whereas the incretin effect is only partially affected.

glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin secretion



Address for reprint requests and other correspondence: E. Ferrannini, Dept. of Internal Medicine, Via Roma 67, 56122 Pisa, Italy (e-mail: ferranni{at}ifc.cnr.it)




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
R. Padidela, M. Patterson, N. Sharief, M. Ghatei, and K. Hussain
Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period
Eur. J. Endocrinol., January 1, 2009; 160(1): 53 - 58.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Muscelli, A. Mari, A. Casolaro, S. Camastra, G. Seghieri, A. Gastaldelli, J. J. Holst, and E. Ferrannini
Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients
Diabetes, May 1, 2008; 57(5): 1340 - 1348.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
F. K. Knop, T. Vilsboll, P. V. Hojberg, S. Larsen, S. Madsbad, A. Volund, J. J. Holst, and T. Krarup
Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State?
Diabetes, August 1, 2007; 56(8): 1951 - 1959.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Salinari, A. Bertuzzi, M. Manco, and G. Mingrone
NEFA-glucose comodulation model of beta-cell insulin secretion in 24-h multiple-meal test
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1890 - E1898.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.